Skip to main content

Table 1 Baseline Characteristics and Direct Acting Antiviral Outcomes compared between Immigrant and Canadian Born Patients

From: Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants

 

Immigrant to Canada

(n = 134)

n (%)

Canadian Born

(n = 591)

n (%)

P Value

Male Sex

70 (52.24)

406 (68.70)

< 0.001

Race

n = 114

n = 511

< 0.001

 White

53 (46.49)

460 (90.02)

 Black

10 (8.77)

11 (2.15)

 South East Asian

24 (21.05)

5 (0.98)

 East Indian

26 (22.81)

3 (0.59)

 Indigenous

1 (0.88)

32 (6.26)

Genotype

n = 129

N = 571

< 0.001

 1a

24 (18.60)

311 (54.47)

 1b

38 (29.46)

53 (9.28)

 1 other subtype

4 (2.33)

10 (1.75)

 2

13 (10.08)

59 (10.33)

 3

32 (24.81)

134 (23.47)

 4

13 (10.08)

2 (0.35)

 6

5 (3.88)

2 (0.35)

Fibrosis Stage

N = 119

N = 523

 

 Stage 1

49 (41.18)

209 (39.96)

0.589

 Stage 2

20 (16.81)

117 (22.37)

 Stage 3

18 (15.13)

71 (13.58)

 Stage 4 (Cirrhosis)

32 (26.89)

126 (24.09)

Currently Employed

54 (40.30)

141 (23.86)

0.004

Incarceration History

11 (8.21)

154 (26.06)

< 0.001

Received Blood Product

19 (14.18)

64 (10.83)

0.293

Alcohol (Past Use)

52 (38.81)

218 (36.89)

0.693

Alcohol (Current Use)

40 (29.85)

177 (29.95)

> 0.999

Recreational Drug Use (Ever)

35 (26.12)

410 (69.37)

< 0.001

Antiviral Treatment Naïve

40/69 (57.97%)

244/345 (70.72%)

0.037

Initiated a DAA Regimen

76/134 (56.72%)

295/591 (49.92%)

0.155

SVR (Intent-to-Treat)

68/76 (89.47%)

270/295 (91.52%)

0.575

  1. DAA Direct Acting Antiviral, SVR Sustained Virological Response